Cytokinetics, Inc. (CYTK)

[H2R]

Smith on Stock has another positive article on CYTK

Cytokinetics: I Predict Amgen Will Proceed to Phase 3 Trials with Omecamtiv Mecarbil

Smith writes he would be very surprised if Amgen did not move OM into Phase 3.

CYTK has three blockbuster potentials in its pipeline:

- Tirasemtiv in phase 3 trial in ALS (Note: has been granted orphan drug designation and fast-track status by the U.S. Food and Drug Administration, as well as orphan medicinal product designation by the European Medicines Agency for the potential treatment of people with ALS)
- Omecamtiv Mecarbil, a very likely Ph 3 (the subject of Larry Smith's article)
- CK-107 (potential SMA treatment), a bit further away

Long CYTK. A couple of years before seeing results, worth the wait in my book.